SELLAS reports 41% lower leukemia death risk

Sellas Life Sciences said its experimental cancer vaccine galinpepimut-S (GPS) met the primary endpoint in a Phase 3 trial involving high-risk patients with acute myeloid leukemia, reducing the risk of death by 41% compared with best available treatment. Median overall survival was 24 months for patients receiving GPS, versus 14.7 months for those receiving comparison treatments, and the company reported no new safety concerns. Sellas plans to meet with the FDA and advance preparations for a biologics license application. The results also prompted a STAT columnist to acknowledge that their earlier prediction the vaccine would fail to extend survival was wrong.



